| Revenue growth | 16% YoY Standalone; ₹304.17 Cr reported. |
|---|---|
| Margins | Standalone EBITDA margin expanded from 3% to 8% YoY. |
| Demand visibility | Strong outlook for cephalosporin antibiotics across emerging markets. |
| Management confidence | High, citing inflection point and integrated platform benefits. |
Growth
Standalone Revenue grew 16% YoY to ₹304 Cr. Standalone EBITDA surged 178% YoY to ₹25 Cr; PAT turned positive at ₹12 Cr vs loss of ₹3 Cr YoY.
Outlook
Focusing on KSM, FDF, and innovative products. Integration complete with multiple growth engines moving from concept to execution.
Risks
Other income declined 38% standalone. Financial results for prior periods were revised to reflect the amalgamation effects.
Last quarter's promises, checked
Delivered
- Guided FY27 base business growth 10-15% → delivered 16% YoY (= BEAT)
- Guided FY27 EBITDA margin ~12% for base business → delivered 8% Standalone (= MISS)
- Guided Dhanuka-Orchid merger completion shortly → delivered Effective July 10, 2026 (= BEAT)
Partly delivered
- Guided 7ACA commissioning Q1CY27 → delivered Project remains on track (= PARTIAL)
Missed
- Guided Enmetazobactam deal every quarter → delivered No new deal announced (= MISS)
Investor Presentation filed with NSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹1,064.90
- Market cap
- ₹6,377 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 735.8×Sector 50.4×
- Promoter holding
- 69.84%+0.00% QoQ
- FII holding
- 0.80%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Capital Structure Change
Orchid Pharma Limited received trading approval for 4,45,86,052 equity shares issued under its NCLT-sanctioned scheme of amalgamation, effective September 23, 2026.
Orchid Pharma Acquisition
Orchid Pharma purchased land in Patibulum Village, Kancheepuram District. This transaction concludes the previous lease arrangement with DBS Bank regarding the property.
Orchid Pharma Annual Report
Orchid Pharma has filed its Annual Report for the financial year 2025-26, which includes the notice for the company's 33rd Annual General Meeting.
Orchid Pharma Annual General Meeting
Orchid Pharma Limited has issued the notice for its 33rd Annual General Meeting scheduled for September 29, 2026, to conduct ordinary and special business.
Orchid Pharma Management Change
Orchid Pharma Limited announced the redesignation of Mr. Arjun Dhanuka as Executive Director and the appointment of M/s. J Karthikeyan & Associates as Cost Auditors.
Orchid Pharma Board Meeting Outcome
Orchid Pharma appointed a cost auditor and designated Mr. Arjun Dhanuka as a Whole-Time Director. The board also set arrangements for the upcoming 33rd Annual General Meeting.